↓ Skip to main content

Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients

Overview of attention for article published in Diagnostic Pathology, February 2018
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • One of the highest-scoring outputs from this source (#9 of 1,184)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news
6 news outlets
twitter
3 X users

Citations

dimensions_citation
33 Dimensions

Readers on

mendeley
31 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patients
Published in
Diagnostic Pathology, February 2018
DOI 10.1186/s13000-018-0690-3
Pubmed ID
Authors

Robert W. Cook, Brooke Middlebrook, Jeff Wilkinson, Kyle R. Covington, Kristen Oelschlager, Federico A. Monzon, John F. Stone

Abstract

The DecisionDx-Melanoma test provides prognostic information for patients with cutaneous melanoma (CM). Using formalin-fixed paraffin-embedded primary tumor tissue, the RT-PCR-based test classifies patients into a low- (Class 1) or high-risk (Class 2) category for recurrence based on expression of 31 genes. The current study was designed to assess the analytical validity of this test. Inter-assay, inter-instrument, and inter-operator studies were performed to evaluate reliability of the 31-gene expression test results, sample stability and reagent stability. From March 2013 through June 2016, the gene expression test was performed on 8244 CM tumors. De-identified data from Pathology Reports were used to assess technical success. Robust sample and reagent stability was observed. Inter-assay concordance on 168 specimens run on 2 consecutive days was 99% and matched probability scores were significantly correlated (R2 = 0.96). Inter-instrument concordance was 95%, and probability scores had a correlation R2of 0.99 (p < 0.001). From 8244 CM specimens submitted since 2013, 85% (7023) fulfilled pre-specified tumor content parameters. In these samples with sufficient tumor requirements, the technical success of the test was 98%. DecisionDx-Melanoma is a robust gene expression profile test that demonstrates strong reproducibility between experiments and has high technical reliability on clinical samples.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 31 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 31 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 4 13%
Student > Doctoral Student 3 10%
Other 3 10%
Researcher 3 10%
Student > Bachelor 2 6%
Other 6 19%
Unknown 10 32%
Readers by discipline Count As %
Medicine and Dentistry 10 32%
Biochemistry, Genetics and Molecular Biology 4 13%
Engineering 3 10%
Computer Science 1 3%
Immunology and Microbiology 1 3%
Other 1 3%
Unknown 11 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 47. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 July 2023.
All research outputs
#877,523
of 25,163,238 outputs
Outputs from Diagnostic Pathology
#9
of 1,184 outputs
Outputs of similar age
#21,669
of 457,711 outputs
Outputs of similar age from Diagnostic Pathology
#2
of 17 outputs
Altmetric has tracked 25,163,238 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,184 research outputs from this source. They receive a mean Attention Score of 3.4. This one has done particularly well, scoring higher than 99% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 457,711 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 17 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 94% of its contemporaries.